Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

Journal of Experimental Medicine

Volumn 183, Issue 5, 1996, Pages 1965-1971

  Topalian, Suzanne L ^a   Gonzales, Monica I ^a   Parkhurst, Maria ^a   Li, Yong F ^a   Southwood, Scott ^b   Sette, Alessandro ^b   Rosenberg, Steven A ^a   Robbins, Paul F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CYTEL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; HLA DR3 ANTIGEN; MONOPHENOL MONOOXYGENASE;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MOLECULAR SEQUENCE DATA; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS;

EID: 0029979997     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.183.5.1965     Document Type: Article

References (32)

1. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Wash. DC). 269:1281-1284.
2. Robbins, P.F., M. El-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella, and S.A. Rosenberg. 1996. A mutated B-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185-1192.
3. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
4. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J.-P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
5. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.F. Robbins, A. Sette, E. Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
6. Wang, R.-F., P.F. Robbins, Y. Kawakami, and S.A. Rosenberg. 1996. A novel human cancer antigen resulting from translation of an alternative open reading frame of TRP-1. J. Exp. Med. In press.
7. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.-H. Meyer zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24: 759-764.
8. Kang, X., Y. Kawakami, M. El-Gamil, R. Wang, K. Sakaguchi, J.R. Yannelli, E. Appella, S.A. Rosenberg, and P.F. Robbins. 1995. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol. 155:1343-1348.
9. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer. 58:69-70.
10. + T lymphocytes. J. Interferon Cytokine Res. 15:739-746.
11. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA. 91:9461-9465.
12. + T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:741-745.
13. Topalian, S.L., D. Solomon, and S.A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714-3725.
14. Bouchard, B., B.B. Fuller, S. Vijayasaradhi, and A.N. Houghton. 1989. Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J. Exp. Med. 169:2029-2042.
15. Sidney, J., C. Oseroff, S. Southwood, M. Wall, G. Ishioka, F. Koning, and A. Sette. 1992. DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DRB1 alleles. J. Immunol. 149:2634-2640.
16. Sette, A., S. Buus, S. Colon, C. Miles, and H.M. Grey. 1989. Structural analysis of peptides capable of binding to more than one Ia antigen. J. Immunol. 142:35-40.
17. Vijayasaradhi, S., Y. Xu, B. Bouchard, and A. N. Houghton. 1995. Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J. Cell Biol. 130:807-820.
18. Chicz, R.M., R.G. Urban, W.S. Lane, J.C. Gorga, L.J. Stern, D.A.A. Vignali, and J.L. Strominger. 1992. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature (Lond.). 358:764-768.
19. Brown, J.H., T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Urban, J.L. Strominger, and D.C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (Lond.). 364:33-39.
20. Geluk, A., K.E. Van Meijgaarden, A.A.M. Janson, J.W. Drijfhout, R.H. Meloen, R.R.P. De Vries, and T.H.M. Ottenhoff. 1992. Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J. Immunol. 149:2864-2871.
21. Geluk, A., K.E. Van Meijgaarden, S. Southwood, C. Oseroff, J.W. Drijfhout, R.R.P. de Vries, T.H.M. Ottenhoff, and A. Sette. 1994. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152:5742-5748.
22. Sette, A., J. Sidney, C. Oseroff, M.-F. del Guercio, S. Southwood, T. Arrhenius, M.F. Powell, S.M. Colon, F.C.A. Gaeta, and H.M. Grey. 1993. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151:3163-3170.
23. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
24. Kwon, B.S., A.K. Haq, S.H. Pomerantz, and R. Halaban. 1987. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc. Natl. Acad. Sci. USA. 84:7473-7477.
25. Lipford, G.B., S. Bauer, H. Wagner, and K. Heeg. 1995. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine. 13:313-320.
26. Zhou, B.-K., R.E. Boissy, S. Pifko-Hirst, D.J. Moran, and S.J. Orlow. 1993. Lysosome-associated membrane protein-1 (LAMP-1) is the melanocyte vesicular membrane glycoprotein band II. J. Invest. Dermatol. 100:110-114.
27. Tulp, A., D. Verwoerd, B. Dobberstein, H.L. Ploegh, and J. Pieters. 1994. Isolation and characterization of the intracellular MHC class II compartment. Nature (Lond.). 369:120-126.
28. Rudensky, A.Y., P. Preston-Hurlburt, S.-C. Hong, A. Barlow, and C.A. Janeway, Jr. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature (Lond.). 353: 622-627.
29. d. Science (Wash. DC). 256:1817-1820.
30. Chicz, R.M., R.G. Urban, J.C. Gorga, D.A.A. Vignali, W.S. Lane, and J.L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27-47.
31. Romero, P., C. Pannetier, J. Herman, C.V. Jongeneel, J.-C. Cerottini, and P.G. Coulie. 1995. Multiple specificities in the repertoire of a melanoma patients'cytolytic T lymphocytes directed against tumor antigen MAGE-1. A1. J. Exp. Med. 182: 1019-1028.
32. Chen, Y.-T., E. Stockert, S. Tsang, K.A. Coplan, and L.J. Old. 1995. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. Natl. Acad. Sci. USA 92:8125-8129.